These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26070452)

  • 1. Caffeine consumption and exacerbations of chronic obstructive pulmonary disease: retrospective study.
    Lopes PO; Alfaro TM; Lopes P; Cunha RA; Cordeiro CR
    Rev Port Pneumol (2006); 2015; 21(5):271-5. PubMed ID: 26070452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
    Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
    Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperpolarized (3)He ventilation defects used to predict pulmonary exacerbations in mild to moderate chronic obstructive pulmonary disease.
    Kirby M; Pike D; Coxson HO; McCormack DG; Parraga G
    Radiology; 2014 Dec; 273(3):887-96. PubMed ID: 24960283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.
    Anzueto A; Niewoehner DE; Leimer I; Rühmkorf F; Celli BR; Decramer M; Tashkin DP
    Respir Med; 2013 Dec; 107(12):1912-22. PubMed ID: 23969305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exacerbations of chronic obstructive pulmonary disease.
    Wedzicha JA; Donaldson GC
    Respir Care; 2003 Dec; 48(12):1204-13; discussion 1213-5. PubMed ID: 14651761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between coffee and caffeine intake and risk of COPD: Findings based on NHANES 2007-2012.
    Liao WZ; Li JX; Feng WY; Xiao JQ; Wang ZX; Xie SJ; Hu YM; Mao JH; Huang ZM; Guo XG; Guan WJ
    Heart Lung; 2024; 67():53-61. PubMed ID: 38701700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A longitudinal study evaluating the effect of exacerbations on physical activity in patients with chronic obstructive pulmonary disease.
    Ehsan M; Khan R; Wakefield D; Qureshi A; Murray L; Zuwallack R; Leidy NK
    Ann Am Thorac Soc; 2013 Dec; 10(6):559-64. PubMed ID: 24053416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
    Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
    Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of clinical outcomes and health care resources in moderate and in severe COPD treated uniquely with tiotropium 18 mcg od for twenty-four months.
    Dal Negro RW; Bonadiman L; Micheletto C; Tognella S; Turati C; Turco P
    Pulm Pharmacol Ther; 2011 Aug; 24(4):373-6. PubMed ID: 21421072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial periodontal treatment for prevention of chronic obstructive pulmonary disease exacerbations.
    Kucukcoskun M; Baser U; Oztekin G; Kiyan E; Yalcin F
    J Periodontol; 2013 Jul; 84(7):863-70. PubMed ID: 23003917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations.
    Farland MZ; Peters CJ; Williams JD; Bielak KM; Heidel RE; Ray SM
    Ann Pharmacother; 2013 May; 47(5):651-6. PubMed ID: 23585645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Etiology and biomarkers of systemic inflammation in mild to moderate COPD exacerbations].
    Saldías PF; Díaz PO; Dreyse DJ; Gaggero BA; Sandoval AC; Lisboa BC
    Rev Med Chil; 2012 Jan; 140(1):10-8. PubMed ID: 22552550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low inspiratory capacity to total lung capacity ratio is a risk factor for chronic obstructive pulmonary disease exacerbation.
    Zaman M; Mahmood S; Altayeh A
    Am J Med Sci; 2010 May; 339(5):411-4. PubMed ID: 20375693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between incidence of acute exacerbation and medication therapy in patients with COPD.
    Suh DC; Lau H; La HO; Choi IS; Geba GP
    Curr Med Res Opin; 2010 Feb; 26(2):297-306. PubMed ID: 19961283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic analysis of antimicrobial therapy of chronic obstructive pulmonary disease exacerbations.
    Simoens S; Decramer M; De Coster S; Celis G; Laekeman G
    Int J Clin Pract; 2007 Feb; 61(2):200-6. PubMed ID: 17263707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels.
    Wedzicha JA; Seemungal TA; MacCallum PK; Paul EA; Donaldson GC; Bhowmik A; Jeffries DJ; Meade TW
    Thromb Haemost; 2000 Aug; 84(2):210-5. PubMed ID: 10959691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study.
    Corhay JL; Vincken W; Schlesser M; Bossuyt P; Imschoot J
    Int J Clin Pract; 2013 Dec; 67(12):1294-301. PubMed ID: 24246208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.